Latest / The Thyroid (and Hormone) Fixer Podcast: Thyropause, Menopause, Metabolism and How to Fix It / 569. Testosterone Breakthrough: A New Testosterone Solution Rocking the HRT World with Shalin Shah
Transcript
- 0:00Now you have another tool to look at the overall picture, right? A lot of people have these normal T levels, high SHBGs and low free T levels. I see that from a lot of our providers day in and day out. And I'm just like, what do we do? So in some sense, you don't need the T a lot higher. You just really need to free up the free testosterone and work on that ratio. And if you can do that, bingo.
- 0:23Welcome to the Thyroid Fixer podcast, where we dive deep into the world of thyroid and hormones, especially for you ladies navigating perimenopause and menopause, and really for anyone struggling with hypothyroidism. I'm your host, Dr. Amy, thyroid and hormone specialist and CEO of a global telemedicine practice where we prescribe the right thyroid treatment and bioidentical hormones to all 50 states and most of Canada, helping you become that badass human that you're meant to be.
- 0:53So if you're battling weight gain and hair loss, you can't lose weight no matter what you do, your energy levels are plummeting and your libido left town, then you're in the right place and you have found your tribe. Remember, I want you to embrace every inch of that badass woman that you truly are. So if you're ready to dive in and fix things, let's get started.
- 1:15Now, you all know that one of my favorite hormones, second to thyroid hormone, NT3 and T2, is the get shit done hormone, testosterone.
- 1:25Now, I want to preface this episode with I am by no means associated with or get any kind of financial kickback from Marius Pharmaceuticals or Kaizotrex. But what we're talking about today is pretty groundbreaking. So Shaolin Shaw, I actually met him. He's the CEO of Marius Pharmaceuticals. And just get the pharmaceutical thing out of your head. No, it's not like Bayer or Pfizer, Big Pharma. Yeah.
- 1:53CEOs coming on. Shailen Shaw has a groundbreaking testosterone therapy that can really change lives of men and women alike. And when I heard about Kaizotrex, that's the name of the FDA approved oral testosterone on market now, when I first heard about it, I thought, oh my gosh, this is just groundbreaking.
- 2:16Because as you'll hear in this episode, you'll hear me ask him about oral testosterone and how we've been taught to avoid it. The destruction of the liver, how it will increase SHBG. We want to stay away from oral tea. But Kyzotrex is different. So I really...
- 2:34feel strongly about bringing this information to you, the patient, the consumer, but also to any of my prescribers, practitioners, doctors, NTs, anyone out there in the TRT world. And
- 2:50Bring this information to you as another option. It might not be right for everyone, but it's another option that we have on the table to allow everyone, every single patient out there, every single person out there to enjoy the benefits of testosterone from the way that we feel, the way we look, the way we perform. But even that protection against cancer, against cardiovascular disease that we talk about in today's episode.
- 3:16So I just want to start off by saying, no, there's no financial gain for me talking about a drug on the Thyroid Fixer podcast. This is specifically to bring you this information so that you can talk to your practitioner. You can talk to us if you're a patient of ours and figure out whether or not Kaisotrex is an option for you or is a better option for you.
- 3:44So most of my audience knows that I absolutely love testosterone. I call it the get shit done hormone. I talk about how it is required for both sexes, male and female. And it's one of those hormones, and I know you're going to agree with me on this, that we need to educate not only the general population about the importance of their own testosterone levels as it relates to their health and various diseases, but we also need to educate people
- 4:12practitioners and doctors and physicians that testosterone is, number one, not just for dudes. Number two, women need it too. And number three, just the importance of it as it relates to our whole health picture, including longevity. So, Shalin, thank you so much for jumping in and being with me today to get this message out, to educate, inform, empower people everywhere from the practitioner side down to the patient consumer side.
- 4:41Thanks for having me, Amy. Yeah, real pleasure to be here and excited to dive into the conversation. And like you said, just frankly, kind of share more, right, for both patients and practitioners. Exactly. So as I said in the intro, you are the CEO of Marriott's Pharmaceuticals and came out with a brand new oral form of testosterone that we're going to be unpacking today. But before we get into that specifically, before we get into Kaizotrex,
- 5:07I want to talk about testosterone in general and how important it is for both sexes. Like I said in the beginning, I also find it important when my audience hears it from someone other than me, when I can actually bring on an expert to say like, see, he's saying the same thing that I say.
- 5:24So I'm going to start there. I'm going to start there. TRT. When did testosterone replacement therapy even begin in the United States? When did we start using this on men? And when did we start recognizing that, hey, this hormone called testosterone really starts to drop after a man turns 40?
- 5:43It's been a bit of a, I'll call it tidal wave to a certain degree. I think really in earnest starting in the 80s, a lot of practitioners back then, still much like today, were apprehensive and it was small. And we've had our ups and downs, right? There was a growing use in the 80s to a certain degree.
- 6:00Late that decade, you had the Olympic scandals and that sort of set testosterone back because Congress actually made it a controlled substance, right? The only hormone to be so, frankly, it doesn't make any sense, but that's added a lot to this stigma. Then you saw some decline in the 90s before it started picking up again. Early 2000s saw some really good research around testosterone and its link to diabetes, right? Our testosterone deficiency and the link to diabetes. Yeah.
- 6:26And that continued to grow until in 13, 14, there were some faulty studies around testosterone and cardiovascular risk. And that set the field back quite a bit. And that was actually quite a significant blow because it was just unfounded. And it was terrible research that led to it. Similar to the WHI has really come full circle and everyone is talking about. There was a great panel last week, two weeks ago from the FDA.
- 6:50So testosterone has been a long way, but underlying this whole, let's call it patient movement or whatnot, right? The research, the good research has been so significant and it's been across the board as we're talking about testosterone being a metabolic hormone, whether that is related to the neuro side. So brain function or cardiovascular function, bone, muscle, naturally, yes, your libido and the list just keeps going, right? And it goes even deeper to cellular levels.
- 7:20You know, that research is significant and volumeless to a certain degree that patients can dive into. But I think if we look at where we are today in 2025, we're finally getting this back on track. Practitioners like yourself that are out there educating. So I feel pretty good about what that means for patients for the next 5, 10 years. And this, what I call a bit of a hormone renaissance that is starting to bloom, if you will.
- 7:45And I love that. I love hormone renaissance because you can feel it with the new focus on menopause, perimenopause, with many experts coming out talking about that and it becoming more mainstream. Just like you referenced, the WHI initiative, the Women's Health Initiative study that really, I mean, set us way, way back as it ripped hormones out of women's hands left and right.
- 8:05and put the fear of God into doctors prescribing them. Now we have that information of the downsides of that study as the authors have come out and said so themselves. So we are starting to see this shift and I love it. But just like we're focused on perimenopause, menopause and estrogen and progesterone, I always feel like testosterone gets left behind a little bit.
- 8:26And even with the experts talking about menopause, they focus so much on the female hormones that I feel that women almost get the message themselves that testosterone isn't that important and isn't as important as estrogen and progesterone. So you had mentioned a few of the benefits.
- 8:42Can we go a little bit deeper and expand on those? You mentioned even protection against bone, obviously calling it the get shit done hormone. There's the motivation factor. There's that drive. There's energy, body composition. What else? What else?
- 8:57So think about, I mean, so let's even talk about the drive, the get you done aspect, right? So if you look at the flip side for testosterone deficiency, there was a really good study that was done about a thousand patients. This was male. For the listeners, there's no reason to segment male versus female in the sense that
- 9:15testosterone, it works across the body in similar ways, right? Obviously, yes, in different amounts and certain aspects of the body may be a little more receptor dense than others. But at large, I think it's fair to say that this works similarly across bodies or sexes rather. But on the sort of the mental bit for testosterone deficiency, again, 1,000 patients with low testosterone, 92.7% reported depressive symptoms. And of that, 20% were major depressive symptoms.
- 9:44And this is pre-therapy. Post-therapy on testosterone replacement therapy, that 20% of major depressive symptoms went down to 2%. Massive delta, right? So we talk a lot about getting in an upward spiral. I'm a big believer in a lot of the fundamentals, right? Whether that is exercise, whether that's sleep, whether that's nutrition, stress management, right? But if you are in this negative vortex, right?
- 10:07I mean, there are some weeks that are, but even for me, it's hard to get all those things done, right? So if you're in a negative vortex, there's no way in the world you're gonna accomplish these fundamentals. So it's kind of this chicken and the egg thing. What are you gonna help this person do, enable them,
- 10:23so they can make the changes that they need. A lot of them are lifestyle, right? I think there's this problem of testosterone deficiency in both sexes have occurred for different reasons. A good portion on the male side is lifestyle. It is our sleep. It is our stress levels. Can you fix all of these? No. The environmental toxins are a tough one, right? That's going to be tough to weed out, at least in the short term. So you want to still give yourself the best shot.
- 10:47that you can at improving these things. And I think testosterone kind of being a foundational, the next foundational level beyond the fundamentals is certainly where it sits. And yeah, happy to get into whether that's bone, muscle, right? You want to be, muscle is an endocrine hormone itself, right? So it's excreting these processes across the body. If you don't have adequate muscle, it's not going to function properly, right? So it's cardiovascular, endothelial linings, right? People don't think about cardiovascular disease. So
- 11:16I think the easiest way, honestly, to put it for those thinking about, okay, hey, how big of a problem is testosterone deficiency and how important is it to meet? Large-scale studies link testosterone deficiency with all-cause mortality, higher all-cause mortality. So what does that mean? You will die sooner if you have testosterone deficiency than you would otherwise.
- 11:37And that's because that low testosterone is linked to the diseases that can come from having low testosterone. So having low testosterone directly isn't going to kill you. It's because that low T is going to increase your risk of type 2 diabetes, cardiovascular disease, diabetes.
- 11:54dementia even, and even cancer, right? Four horsemen, the biggest diseases that are talked about in the longevity space and just general health at large. Testosterone has a link to all of them. It does. There is that direct link with testosterone and cancer. I interviewed a functional oncologist on the show, and she actually gave the story of...
- 12:12a patient of hers who was basically stage four given six months to live. And she thought, well, what the hell? I'm just going to jack his testosterone up and we'll see what happens to give him quality of life because he had all of the what I'll call the first bucket of those noticeable symptoms.
- 12:28The erectile dysfunction, the belly fat, the fatigue, the brain fog, the cognition, the depression. Of course, he was dealing with a cancer diagnosis as well. She gives him testosterone and ends his life by a few years. So, yes, there absolutely is that correlation with cancer and, like you said, all-cause mortality. Now, you had mentioned cardiovascular. So now I want to go to some of the myths out there floating around of how testosterone is bad.
- 12:55And I'll start with a story. So my husband, of course, I tested him when we first started dating. I'm like, honey, let's check your testosterone levels, right? It's greener. Yeah. This is a requirement for dating. You need to have adequate testosterone levels. And he was low. So we started him on injectable testosterone, sydney, which we'll get into later in this conversation, the different forms and the pros and cons of them.
- 13:18One of his doctors, not in my practice, outside his PCP basically said, well, that AFib that you're having, that little bit of a heart palp, that's because of the testosterone. So it scared the bejesus out of him. And he's starting to second guess his TRT. And I'm like, no, honey, that's not it at all. Testosterone is going to protect your muscle. So can we talk about the cardiovascular myth out there? And let's bring in the prostate too and PSA levels and prostate cancer.
- 13:47Yeah, so these are two of the largest myths when it comes to TRT. And as we stand today, through research, right, large-scale clinical trials, they have actually been put to bed, right? So Traverse is the best place to, and even pre-Traverse, it was known, but I think if anybody really wants to sort of
- 14:05fight that battle, then you just point to Traverse. And that's unequivocally demonstrating that there is no cardiovascular risk with testosterone therapy and there is no prostate cancer risk with testosterone therapy. And just for the listeners, right, this was a 5,000 patient double-blinded placebo-controlled trial that...
- 14:23was effectively mandated by the FDA back in 2014, probably cost, I don't know, upwards of three, $400 million to complete by industry. And it finally read out in the New England Journal of Medicine in June of 2023. So it was actually just poor, faulty studies that led to this overblown concern.
- 14:44And actually an interesting stat I'll share is we surveyed primary care not too long ago, only a few months ago, right? So we're still talking two years post-release of this study. And I think the number was 84% still had not heard of Traverse and the data. So it's very tough for patients to then go in and have to sort of fight for their right, if you think about it, for TRT. And then they get second-guessed and they're asking around and that leads to inaction, which is only detrimental. So...
- 15:13Yeah, actually, I think you'll see a lot of the conversation actually shift to how this is cardioprotective. Same thing on the cancer side. There was an interesting study done two, three years ago, and it looked at, this was actually colectal cancer, TRT, and the rates were actually 25% lower on testosterone. So it's a long process of reeducating both that patient and provider, but I think there's a significant wind that I feel out there that's helping.
- 15:40Oh, huge. Yeah, I do think we're starting to see the winds of change with this, but we need to go a little bit faster. So you touched on this. I think another barrier for the consumer, the patient to obtain proper TRT therapy is that it's a scheduled drug.
- 15:58And so I'm going to throw out my theory. I've said it before. I'm going to throw it out and get your opinion. But my unsupported hypothesis on why testosterone has been placed into a very difficult category. Basically, what we mean by scheduled is that a provider has to have a DEA license to prescribe testosterone. And think of it, it's in the same categories as opioids, if I'm not wrong.
- 16:21It's just one category, Bob, but often get looped together. So they're scheduled to, but still, a lot of places treat them the same. So the logistical hurdles, there's no difference. Right. And you have to have that DEA license to prescribe. So making it very difficult, my theory is that because testosterone,
- 16:39can help get men and women off of antidepressants, statins, blood pressure medications, sleeping pills, Viagra, Cialis, and XYZ. Gee, if we make that easy, those pharmaceutical companies take a really big hit if they're not getting the amount of sales from the statins and the antidepressants, which are two of the most prescribed medications out there. So that's my theory. I don't know if you have a different thought on this, but that's my theory.
- 17:06It's in line. Mine is in line as well, right? I think it is a little, it's called too good to be true and it affects a lot of the research. Like I mentioned, even the statins and the depressants are in some sense that low-hanging fruit. Imagine we talk about cancer. That is a sort of a holy grail of research that you're then going after.
- 17:25And I mean, what's our ultimate goal as a society, right? We want to prevent disease and cure disease. So it's a little disconcerting that that hasn't gotten a little bit more attention and support, if you will. But I think there's definitely some underlying truth to your hypothesis. Well, and then from the insurance company standpoint, I also heard you say on another show that it's easier to get reimbursed for a chronic disease drug than for a mass market drug like testosterone. Is that true? Yeah.
- 17:54Yeah, so most of the drugs that are reimbursed today are these extremely high-priced specialty drugs that are coming from the big pharma players, like you're mentioning. But for a mass-market drug like an oral testosterone, you would think they're, and honestly, affordable too, right?
- 18:09there shouldn't be any hurdles. So it's kind of a backward system because that could then in turn decrease healthcare spending. So, right, like all those things that you mentioned, all those conditions, if you're able to help them, look, not everybody is going to go through, and it's impossible, it's hard for us to do it too, run every study to prove out every indication and whatnot. But when you have enough real world evidence that is pointing in a certain direction, just like the FDA did two weeks ago when FDA commissioner came out and said,
- 18:39for females is important for all of these reasons. That's not on a label, actually. But he understands the research that's been done and the role that they play in the human body. So he's able to make that statement as a physician scientist, right? So I think for testosterone, a lot of the same position can be taken
- 18:58very publicly and you go to payers, this can help their bottom lines. If you look at, if they looked out beyond two years, right? That's the problem. They're only looking out because you're going to switch your job most likely, and I'm not going to cover you in two, three years. So why bother? But if they took a more long-term view, then you would save healthcare costs, significant healthcare costs by something as basic as testosterone therapy.
- 19:21Oh, my gosh. Absolutely. Now, you are you and your team, you have a nonprofit that you're actually fighting to get it rescheduled. Is that true? Yes, that's correct. Yes. So the testosterone project, descheduling is a top priority for us. And actually, we've had a lot of conversations around this. Granted, the new administration is some of the departments are in a bit of flux and so forth. So that's really where we're.
- 19:44kind of pending, if you will. But yeah, I think the case is very strong. You haven't seen abuse in this class. Oral testosterone is even harder to abuse, right? Because you're not going directly into the bloodstream with super physiological levels. So I think there's even a better case there unbiasedly. But ultimately, it's about axiomist and stigma. So how do we remove this for patients and providers? So we want a healthier population.
- 20:08I love that you're doing that. I just love that you're fighting for it because it's so important. It's such an important hormone. So good luck with that. And please let us know if we get healthier and any way I shape or form. Interesting revolution, right? That's really what we need. I think if we can have, that's what we need to sort of bring to Washington's front door. And that's when they listen. Yeah.
- 20:26Exactly. Just keep knocking, right? So yeah, you had mentioned oral, oral testosterone. That's what Kaisachex is. So I want to go deeper into that. But before we do, let's talk about the different forms out there that are more common for men and women, and then even the pros and cons around those. So we'll start with the men. So for men, yeah, there's gel, which I'm
- 20:44I've got to tell you, I've never seen it really work well for men. I mean, nine times out of ten, they're not compliant with it. They're not rubbing it in properly. And then there's the downsides of transference from if a man puts on a gel and uses a towel and then the woman grabs the towel or your child grabs the towel. Or what if you don't wash your hands good enough and you touch your dog? There's all of these things. And we can also say that for people.
- 21:07the compounded cream that we use for women. And there's some downsides with the cream that I'm very vocal about. It does push up DHT more so than other forms. So I tend to, in our practice, we use injectable for nine times out of 10. Male and female will use injectable. And then of course, there's the different esters of the injectable. There's cipionate and they propionate with different half-lives. So now comes along Kaisotrex and it's oral. And in my past, coming from the bodybuilding world,
- 21:37Oral testosterone or the oral forms of anabolic drugs, we'll say, we all knew like, ooh, that guy's going to pound his liver because he's taken that oral. But that's not the case with Kaisotrex. So I want to really unpack all the benefits of oral dosing of testosterone from using Kaisotrex, not just any old oral form that you get on the black market from the guy at the gym, but using Kaisotrex in oral form versus those other delivery methods.
- 22:04Sure. So yeah, I think the first thing like you mentioned is this whole historical past around liver toxicity. And that's still a common misconception to this day, even when we start our conversations around Kaisotrex in that sense. And just precursor, right, Kaisotrex is today, it's only indicated for men with low or no testosterone due to certain medical conditions, right? Whether that's pituitary issues, testy issues, and so forth. So we're working on a
- 22:31Lymphatic absorption. So chysiotrexin is absorbed through the small intestine, right? So we figured out a way here to bypass the liver, uptake through the small intestine, and then into the bloodstream. And so we see no liver toxicity through any of our trials or data. And I think that's a huge breakthrough, right? Because at the end of the day, we understood, one, we understand how important
- 22:53a metabolic hormone testosterone is. And if we have this, let's call it metabolic crisis or testosterone deficiency crisis, how do you solve that at scale, right? Like injectables, like you say, that you use nine out of 10 are very tried and true and reliable, but we know to reach the massive population that needs this, unfortunately not everyone's gonna inject themselves.
- 23:13We live in a world that, yes, people are comfortable taking capsules or pills. You already likely have a pill box with your other supplements. So you're going to add it to your routine and it's going to be seamless. So I think there's a convenience factor that goes sort of without saying with that. But to your first point is that this is not liver toxic. So patients and practitioners alike, they don't need to be worried about that. You do have to take it with food, helps activate the lymphatics, and then it will go through that system. But you do not have to worry about historical safety issue.
- 23:43That's one big thing. The other big thing here is what we see now is that because this is taken daily, you're effectively mimicking your natural circadian rhythm, right? Hormones are produced every day in the body. When you're sleeping, you're producing your hormones, and that's why I think they're so messed up today because our sleep is awful, but you're producing overnight and then peaking in the morning and then going down throughout the day.
- 24:04So Kysotrex is the closest product to mimic that natural circadian rhythm. And you're getting a physiological dose on a daily basis. And I think that's a real important point. And we'll talk about that versus sort of what you see typically in injections. So what it does is then it really mitigates the side effect profile.
- 24:25So some of the things that you typically see with testosterone are elevated hematocrit. And this can be an issue for a number of men that sometimes maybe their dose is a little bit higher, but they're taking it for a couple of days at a time. At least you'll see an elevated hematocrit. Here in our trials, it was sub 2% of patients had elevated hematocrit, sub 2%. Whoa. Oh my gosh. I would say we see about 80% in men and women. I have elevated hematocrit and hemoglobin.
- 24:53Okay. And it's spanning across both. So sub 2% there. And then that would also resolve from a down titration, right? So nobody ever left the trial because of that. We have a KOL that published an abstract on their own practice data. They also were only treating with max dose at 400 milligrams BID. And still...
- 25:13The hematocrit level was very much in line without these excess excursions. So that's an interesting paper as well that's out there. But it's a huge, both for providers and patients, right? Like providers don't really want to worry about your hematocrit like being elevated, right? Did you go and dump blood? I don't know. Did they have time that week? Like it's a big ask.
- 25:32Well, it is because I don't have time to go donate blood. And I know I should. And I know my husband should. But we just don't have time. But that can be not a smart thing to do. You really should go and donate. Right. But think about all the patients out there, right, that are floating around in a similar boat. So that's a big thing. Things like excess estrogen conversion, we don't see. Right. And I think a lot of this all stems from physiological dosing.
- 25:56Oh, wait, you need to pause on that. That's huge. That was in my list of questions to ask you, but that is huge. So just to explain to the audience, I see this more in men than in women because of the doses that we're giving them. So let's take the injectable, right? Testosterone, cypionate, injectable, we're going to dose a man at 200 milligrams per week, whether he splits it up into micro doses or does once a week dosing, whatever, it's around 200 milligrams.
- 26:21And with that, there's that aromatization to estrogen. So of course, we always test a man's ultrasensitive estradiol. We want it there, but we don't want you having zero estrogen. We want some, but we also don't want it high. My husband was, oh goodness, I want to say his estradiol was like 185. That was way too high for a dude. So what does he get put on?
- 26:45anostrozole, an aromatase inhibitor to block that aromatization from testosterone to estrogen. So you're saying, and the AIs, the aromatase inhibitors, they come with their own kind of side effects. They can drop a man's E too low. You just get side effects with the AI as well. So it's kind of like you're treating it. Yeah, exactly. Exactly. So Kaisotrex does not aromatize or aromatizes very, very little.
- 27:09You do not see, unless you have a predisposition, right, to aromatization, which a couple percent of guys do, right, we do not see an excess at an aggregate sort of mean level across our data and anecdotally in a lot of my discussions with clinicians, right, which I'm having every day. AIs are not part of a standard treatment protocol with Kaizotrex.
- 27:28So I think that's really, really nice from just, I mean, one, yeah, one less thing to manage and the side effect profile, you need some estrogen, right? Like I think that's been a problem even with some of the folks on Clomid, right? Like the numbers look really good, but some other blocking mechanisms happening there. And then-
- 27:45They're overly moody and sensitive and just all hell kind of breaks loose on half of those patients, right? So that's a big one that we have not seen. We don't see physiological doses, daily doses. We don't see testicular atrophy. LH and FSH is not dropping to zero. Undetectable levels is what generally happens. That's not what's occurring here.
- 28:04So that's going to also come back and protect fertility in men. Because we do, I mean, let's face it, we have a couple of men right now as patients that they're in their 20s. And they have that hypogonadism that it just, their T levels are coming in at 185. The one gentleman has a T level of 250. I mean, just really, really low.
- 28:27They need to saw storm replacement therapy, period, end of story. But in doing so, they are rolling the dice with their fertility. So, yeah, it's a really interesting concept. I'm not saying chytoflex maintains your fertility, but it does not lead to total suppression of the LH and FSH. Right. And we are running a pilot study, or actually one of our KOLs, Dr. Moly Kerr out of Baylor, is running a fertility study. He's looking at spermatogenesis in patients, young male patients,
- 28:54And I believe he's due for another update on the study. But the last update in the fall, 80% of the patients reported no significant decline in sperm counts on drugs. So I think this is a really, really interesting sort of paradigm because the fertility crisis for young males is massive. And it's partly driven, in fact, by low testosterone, right? But the normal course of therapy would not be the solution, right? You can't give them...
- 29:21high doses of testosterone to return that fertility. But what if you could not affect it, one, or two, maybe there is a case for rising intratesticular levels by sort of pulsing exogenous testosterone. And that would tie back then to that
- 29:38You talked about a circadian rhythm of testosterone. So if we keep that nice and steady, which I think we try to do with injectables when we have men microdose it through the week. So some men, some men like my husband are non-compliant, you just got to do once a week. But other men can actually do microdoses of, let's say, testipionate throughout the week to kind of have that pulsatile effect of testosterone. Correct.
- 30:02With Kaizotrex, you're getting that hands down. With the injectable, it's kind of a crapshoot. You could still get that spike even from a microdose, even from that microdose that you take one day and every other day. Correct. And then you get that crash. But with Kaizotrex, it just keeps you steady.
- 30:20Yeah, you're just pulling in that curve. Can you achieve it if you were injecting yourself every day? But that goes back to my point around scale, right? If you've got 25 million hypogonadal men, we can't expect them to inject every day. It's just not great. No, you're not gonna. So this can solve that.
- 30:35Well, I loved it because I actually asked my husband, I'm like, okay, I know that you're non-compliant with most of the things that I tell you to do. I said, today I'm interviewing Shallon Shaw about Kaiser Trex, but you'd have to take it twice a day. Would you actually do that? He's like, well, yeah, for something like this, I would. This is actually the one time that my non-compliant husband would be compliant because of the benefits.
- 30:57The motivation would be there, right? Yeah, exactly. So I think it kind of introduced like, yeah, nobody wants to take their statin, right? They're like, that's not fun. But I think when you see the benefits of the patient motivation to be compliant goes way up. Yeah, yeah, absolutely. Now I'm going to pull this back to the ladies. So ladies listening, hold on. We're going to tie it back to you. But I have to ask another Mayo question in regards to PSA. Do you see any...
- 31:22we'll say decrease in the incidence of increased PSA that we can see with normal testosterone therapy? So the, yeah, so the average PSA increase in our data is about 0.15. So minuscule increase in PSA. And this goes back to like, you're just not blitzing the system with too much testosterone, right? You're giving what you need for that daily.
- 31:47Overall, there should be some rise in PSA, right? So if you're testosterone deficient, like the PSA actually needs some of that to be active. So even any rise, you're actually just restoring yourself to where you would or should be. So I don't think it's alarming at large in that sense. But yeah, so you don't see an overactivity stimulation there.
- 32:07And that rise is minimal. I mean, with traditional TRT, we can see it rise five points. And then, of course, if you're working with a conventional doctor, he or she is going to break you out. Yep. Sets off all the bells and you're not going to be on that too much longer. No, no. They're going to pull that and then they're going to biopsy your prostate. So not fun. Not fun.
- 32:26Yes. So you see, I think like that's the interesting bit here now, like you see a significant safety paradigm shift that allows patients to have these conversations, providers to have these conversations, and it really introduces a concept of like, let's try it and see how you do.
- 32:42right? Because again, symptoms are the reasons that most people are presenting. I think there's still a conversation for and we'll get there where there's underlying metabolic health that you need to treat and be aware of whether that's fasting insulin levels or inflammation in the body, right? That can be treated through this mechanism. But I am fully conscious of that's a conversation like that's evolving and still has to get there, right? Let's start here. But yeah, those safety things. And one thing I do want to mention on the efficacy side too, and I understand it
- 33:10because of historical reasons and you kind of have this bit of the bodybuilding world and whatnot. A lot of people just said oral testosterone doesn't work, right? They just think, well, you need to get ultra high levels. So I think there's two things that it's important for people to really understand. One is still serum testosterone levels, right? This is the amount of testosterone that's floating in your bloodstream.
- 33:30Remember, the testosterone is binding to receptors and activating them, right? So there's a lot of scientific case for saying that activation is really what matters. Your circulating T-level is a proxy for that, but that doesn't really tell you that everything's bound and active, right? That matters. So I think it's important for people to kind of start to get that concept going.
- 33:52But what helps that is that Kysetrex actually decreases a protein called SHBG and increases free testosterone. And that increase on paper is around two times of an increase for free testosterone. And some of our published papers and posters and whatnot have shown a significantly higher increase, two to four times increase in free tea. So you're getting a physiological tea level, mid-range, right? Which conventional says, well, that's okay. Okay.
- 34:19But your free tea could be four times higher and absolutely crushing it if you want to compare it to any other modality. Okay, so this is huge with SHBG. I talk about this a lot. So just to kind of give a refresher to the audience, sex hormone binding glycolin, I always give the analogy of a train. And your hormones have to jump on this train to be delivered to the receptor sites where they want to go to do their job in your body.
- 34:45Sometimes that train gets really sticky and the hormones jump on and then they can't get off. Usually I always tell my audience too and my patients alike that have elevated SHBG, look, sometimes the very things you're doing for your health...
- 35:02like going low carb, like taking T3, taking estradiol hormone replacement, taking testosterone. Those are the things that can ironically increase your sex hormone binding globulin. So you don't want to throw the baby out with the bathwater. You want to be able to treat that SHBG and bring it down. Now, my fixer line, I have SHBG fixer. And sometimes, you know, I'm telling people, listen, you're just going to take that to put a cap on that SHBG so it doesn't go above the 150 that you're already at.
- 35:29Ultimately, I'd love to see it down around like a 60 or a 70 for both male and female. 60 to 80 is my sweet spot. So when it starts to go above that, it's like, oh, you're going to bind hormones now. What do we do? So you're saying that Kyzotrex can actually be another tool in our toolbox to lower SHBG. That's huge.
- 35:50Yep. Like you say, a lot of folks are running around with high elevated levels today and whether that is a function of age, some of the other hormones like their bodies compensating, right? And raising SHBG to match this influx of endogenous or exogenous to I mean hormones, right? So yeah, now you have another tool to look at the overall picture.
- 36:10A lot of people have these normal T levels, high SHBGs and low free T levels. I see that from a lot of our providers day in and day out. And I'm just like, what do we do? So in some sense, you don't need the T a lot higher. You just really need to free up the free testosterone and work on that ratio. And if you can do that, bingo.
- 36:29Yeah. And actually, so this is the perfect bridge. I find in my practice that women have higher SHBG levels in general than men. And most likely is due to the estrogen replacement or just that we have more estrogen in general. Some women are coming off birth control years, decades. I think it's a huge culprit in this in this equation.
- 36:49Yeah, absolutely. It's huge. It's huge. So for my ladies, Keisotrex is not yet FDA approved. But of course, when you're working with kind of out of the box thinking practitioners, we can still use it with the ladies. Right. In a much lower dose. Right. So, yeah, Keisotrex is not approved for females. We are looking at these programs. Our goal is to bring a female approved product to market.
- 37:12hopefully in a shorter timeframe than what is typical, given Dincey's view on hormone replacement therapy at this point. Based on our initial understanding of where the program needs to be, typically a female dose is one-tenth of a male dose, right? So two things. I don't think it's that hard to figure out what would be an appropriate female dose for our program, right? And we'll have a couple options that we'll run through our trials, so you can titrate appropriately.
- 37:37But yeah, for this general population, it's been highly neglected and a missing part of the puzzle. So I can't, I mean, you'll see this firsthand, right? Like how many females come back after being put on testosterone therapy? How many come back and don't say that they're feeling better, right? I mean, it's pretty much night and day and often probably the day.
- 37:56For seemingly so, the biggest difference maker of the female hormones, whether it's progesterone, estrogen, and just in that feeling, right? And sort of the vigor that they come back with. So I think it's as simple as female testosterone deficiency. It doesn't need to be hypersexual disorder. It doesn't need to be osteoporosis. It needs to be female hypogonadism.
- 38:16It does. It really does. So right now, just for the listeners to understand right now, the only way a woman can get approved for, we'll say, approved for testosterone replacement therapy is if she has the hyposexual disorder or...
- 38:33osteoporosis. That's it. It doesn't matter if she comes in and reports to her general PCP that, hey, doc, I've lost a lot of muscle. I have no libido whatsoever. I have brain fog. I have no motivation. And my testosterone is a five. That's not enough for her to actually get TRT. She actually has to be diagnosed with hyposexual disorder, basically.
- 38:53Yeah, that's the only thing that sort of sanctioned guidelines today, right? And there's only four countries in the world that still approve female products. You know, the USA is. There are probably, by our estimates, at least a million females that are on testosterone replacement in this country. And I think there's a lot through pellets, some on injectables, and then the creams. But think about how revolutionary an oral option would be for that patient population.
- 39:19Oh, my goodness. I'm so happy you mentioned pellets because there's the complete opposite of what Kysetrax does. So pellets, jack of females, testosterone, I have seen it as high as 900 when she is tested one month after pellet insertion because she's at that peak. And I know all the pellet literature out there is like, no, no, it's dispersed evenly throughout those four months that it's in. No, it's not.
- 39:43No, it's not. You get this bolus dose and that's where you get the hair loss and that's where you get all the androgenic symptoms that are irreversible because you can't take the pellet out. So if you're on an oral like Hyzotrex and you have, and that's not going to be my next question to you, but if you're on an oral like Hyzotrex, you can adjust the dose.
- 40:01So let's talk about those androgenic effects. I mean, this applies to male and female. Have you seen in your studies any reduction of those androgenic symptoms that can really hit, especially a woman, can hit her pretty hard when she starts TRT? Yeah. So in our studies, these are all male-based, but we have not really seen that, right? We have not seen the hair loss. The deepening of voice is obviously a big concern with females. I think females are concerned with kind of looking like Arnold Schwarzenegger, like that's not going to happen.
- 40:31I think most, even peri to post-menopausal women struggle with adding muscle or healthy lean muscle, right? This is really what is going to help at the end of the day. So metabolically, that whole picture is going to be improving. I love that. I love that. So for a man, you mentioned earlier, usually 400 milligrams twice a day is on average. So I think it's important for us to say this out loud for anyone who is on TRT because they're going to hear 400 twice a day. I take 200 a week.
- 41:00How does that equate? And then for women, so let's say we went down to, I know Kysetrex comes in 100 milligram capsules. So for women, if we went to 100 milligrams, again, they're going to freak out and go, wait a minute, I'm on 10 milligrams a week of testipionate. If I take 100 a day, won't I turn into a dude? So how is that different from the injectable dosing to the oral Kysetrex dosing? Right.
- 41:23So there's no perfect conversion chart, but since it's oral, we have to look at what the overall bioavailability is, right? So you're going to really be, at the end of the day, it's a couple percent that's going to end up in the bloodstream versus an injectable. It's pretty much 100% is going into the bloodstream. So it's
- 41:38Very different ultimate equation there. And you'll see things like this in other classes too, right? As the oral GLP-1s come out, your patients are going to go from this 2.5, 5, 10 milligrams a week to 20, 30 milligrams at least daily. That's where actually the studies are. So you'll see a similar sort of transition occur when those products actually go oral.
- 41:58But no, ultimately at the end of the day, you have to look at what is then the circulating blood levels. So you might be taking that 400 milligrams BID, but your blood levels are in physiologic ranges. And that's really what counts. So you're not causing excess stress to the liver. There's no liver toxicity and so forth. This is just a bioavailability equation that that's where we dose accordingly.
- 42:21Right. Right. OK. I love this. Now, for prescribers, can this be picked up at Walgreens, called into CVS, or does it have to go through, let's say, a special mail order pharmacy? Where can a prescriber send in a prescription for Kysetrax?
- 42:37So prescribers, yeah, we've actually partnered with a number of compounding pharmacies to distribute the drug. Again, they do not make Kaiser-Trex whatsoever. They have the bottles in stock. Just given that a lot of our sort of prescribing world is used to working with them, so that makes it a lot easier to kind of for that continuity. We've not gone through CVSs and Walgreens of the world because, frankly, that just increases the cost to the patient. So Marius launched Kaiser-Trex as a cash-only product,
- 43:06for better access, right? Even though all of us have insurance, they put up every roadblock and hurdle to getting a therapy that's better for you or you want or need, et cetera. So we actually just made it a cash product to make it more accessible, generally in line with where the market is. And people are already used to paying for their hormones, frankly, out of pocket. So we have a number of pharmacy partners. They're on the website. You can just prescribe through there where you're generally already writing to.
- 43:31Or, yeah, there's mail order options, too, where the patient will get a text message saying, hey, your script is ready and you'll just check out. And a couple of days later, you'll have your medication. So easy. Well, and to your point, and I've heard you mention the pricing before on other shows, it is absolutely in line, if not less than testosterone, even if you pick it up at CVS or Walgreens in your copay.
- 43:55is easily in the hundreds. And then, right, compounding pharmacies, I tell all my patients, we're going to be sending this into a compounding pharmacy. Compounding pharmacies do not accept insurance. Period, end of story. So Casetrex is going to be less than some of my compounding pharmacy prices. Probably, yeah.
- 44:13Yeah, absolutely. Right. I mean, our goal was access at the end of the day, because there's 25 million males with this problem, probably 50, 70 million females with this problem, if not more. Maybe it's a little idealistic, right? We don't want to spend 13 years of R&D and hundreds of millions of dollars of development to then ultimately no one have this thing, right? Like that doesn't make sense. So a little idealistic, but that's our goal and mission.
- 44:36Well, I thank you for that because it's more important to get people feeling good and living their best life than going through 13 years of R&D. So, OK, so for the consumer and then flip me over to the prescriber, where should each set population go to find out more information?
- 44:55So both should land on kysertrex.com, K-Y-Z-A-T-R-E-X.com. Obviously, our patient side of the website will have patient-focused resources and where to go. The provider side will have more targeted provider materials, and they can be on our site as a provider so patients can find them. They'll find out about the website.
- 45:15pharmacies and where they can easily send the prescriptions. And frankly, just also engage with us, right? Like we love talking to clinicians that are exploring this, integrating it deeply into their practice, want to do more research, right? Further, let's call it this metabolic mission.
- 45:31I absolutely love it. We'll put all of that information in the show notes as well. So it's easily accessible to you all listening. So Shalin, thank you so much for coming on and sharing all of this amazing information and just revolutionary treatment for testosterone. I absolutely love it. Thanks so much for having me, Amy. It was a real pleasure and look forward to continuing the dialogue.
- 45:52And again, let us know whatever we can do. Let me know whatever I can do to help you in this mission to get it descheduled and to get women into these studies, too. Yeah, no, absolutely. There will be more to share upcoming. Absolutely. Beautiful. Thank you once again. And thank you all for listening.